Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.65 USD | +0.61% | -0.60% | +12.24% |
13/03 | Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 | |
13/03 | Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.24% | 8.84Cr | |
+5.66% | 11TCr | |
+11.23% | 11TCr | |
-0.38% | 2.23TCr | |
-12.15% | 2.21TCr | |
-7.66% | 1.87TCr | |
-36.52% | 1.76TCr | |
-10.09% | 1.69TCr | |
+3.33% | 1.38TCr | |
+36.58% | 1.25TCr |
- Stock Market
- Equities
- SPRO Stock
- News Spero Therapeutics, Inc.
- Spero Therapeutics : Oppenheimer Adjusts Spero Therapeutics PT to $21 From $19, Maintains Outperform Rating